Showing results (71-80 of 331) with videos related to
Sort By:
Pageof 34
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2010
DDS, 4,4'-diaminodiphenylsulfone, extends organismic lifespanSung Chun Cho, Moon Cheol Park, Bhumsuk Keam, et al.Clinical Lung Cancer|June 6, 2019
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysisRyul Kim, Bhumsuk Keam, Seokyung Hahn, et al.Cancer Research and Treatment|August 22, 2025
Preferential Sensitivity of the EGFR L858M/L861R Mutation to Second-Generation EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung CancerChaelin Lee, Sheehyun Kim, Soyeon Kim, et al.Scientific Reports|February 23, 2022
Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancerVincent Vinh-Hung, Hilde Van Parijs, Olena Gorobets, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2016
Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung CancerJunghoon Shin, Bhumsuk Keam, Miso Kim, et al.Cancer Research and Treatment|March 28, 2019
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean PatientsYeonjoo Choi, Bhumsuk Keam, Miso Kim, et al.Plos One|February 1, 2018
Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitorSehhoon Park, Seunggyun Ha, Se-Hoon Lee, et al.The Korean Journal of Internal Medicine|April 14, 2017
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancerSehhoon Park, Ji-Yeon Kim, Se-Hoon Lee, et al.Clinical Lung Cancer|September 30, 2018
Significance of 18F-FDG PET Parameters According to Histologic Subtype in the Treatment Outcome of Stage III Non-small-cell Lung Cancer Undergoing Definitive Concurrent ChemoradiotherapyEunji Kim, Hong-Gyun Wu, Bhumsuk Keam, et al.The Oncologist|September 27, 2018
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part SarcomaMiso Kim, Tae Min Kim, Bhumsuk Keam, et al.Pageof 34